Bloom Science key facts
- Developer of a biopharmaceutical company intended to advance microbe-based therapeutics for neurological disorders.
- Bloom Science’s last known valuation is $46.0M.
- It has raised $23.0M; the latest was Later Stage VC ($11.0M) in Nov 2024.
- Notable investors include Impact Assets, Joyance Partners, ALS Investment Fund, Apollo Health Ventures, Leaps by Bayer — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Bloom Science: the Monday email on marks, rounds and moves
Bloom Science funding rounds
No funding rounds for Bloom Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Bloom Science valuation
Bloom Science's last known valuation is $46 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Bloom Science investors
7 investors are on record for Bloom Science, including Impact Assets, Joyance Partners, ALS Investment Fund and Apollo Health Ventures.
About Bloom Science
Developer of a biopharmaceutical company intended to advance microbe-based therapeutics for neurological disorders. The company offers a translation of the therapeutic benefit of the ketogenic diet into innovative medicines for serious, life-interrupting illnesses, enabling patients with epilepsy and other neurological conditions to receive proper medication and treatment.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 19
- Website
- bloomscience.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Bloom Science’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.